This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shih, H. A. Articles by Weber, B. L. Search for Related Content PubMed PubMed Citation Articles by Shih, H. A. Articles by Weber, B. L. Social Bookmarking                            What's this?

BRCA1 and BRCA2 Mutation Frequency in Women Evaluated in a Breast Cancer Risk Evaluation Clinic

From the Abramson Family Cancer Research Institute and Departments of Biostatistics and Epidemiology and Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA; Mayo Foundation, Rochester, MN; and Institute of Cancer Research, Sutton, United Kingdom.

Address reprint requests to Barbara L. Weber, MD, Biomedical Research Building II/III, Rm 514, 421 Curie Blvd, Philadelphia, PA 19104; email: weberb{at}mail.med.upenn.edu

PURPOSE: To determine the prevalence of BRCA1 and BRCA2 mutations in families identified in a breast cancer risk evaluation clinic.

PATIENTS AND METHODS: One hundred sixty-four families seeking breast cancer risk evaluation were screened for coding region mutations in BRCA1 and BRCA2 by conformation-sensitive gel electrophoresis and DNA sequencing.

RESULTS: Mutations were identified in 37 families (22.6%); 28 (17.1%) had BRCA1 mutations and nine (5.5%) had BRCA2 mutations. The Ashkenazi Jewish founder mutations 185delAG and 5382insC (BRCA1) were found in 10 families (6.1%). However, 6174delT (BRCA2) was found in only one family (0.6%) despite estimates of equal frequency in the Ashkenazi population. In contrast to other series, the average age of breast cancer diagnosis was earlier in BRCA2 mutation carriers (32.1 years) than in women with BRCA1 mutations (37.6 years, P = .028). BRCA1 mutations were detected in 20 (45.5%) of 44 families with ovarian cancer and 12 (75%) of 16 families with both breast and ovarian cancer in a single individual. Significantly fewer BRCA2 mutations (two [4.5%] of 44) were detected in families with ovarian cancer (P = .01). Eight families had male breast cancer; one had a BRCA1 mutation and three had BRCA2 mutations.

CONCLUSION: BRCA1 mutations were three times more prevalent than BRCA2 mutations. Breast cancer diagnosis before 50 years of age, ovarian cancer, breast and ovarian cancer in a single individual, and male breast cancer were all significantly more common in families with BRCA1 and BRCA2 mutations, but none of these factors distinguished between BRCA1 and BRCA2 mutations. Evidence for reduced breast cancer penetrance associated with the BRCA2 mutation 6174delT was noted.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. W. Gray, C. O'Grady, L. Karp, D. Smith, J. S. Schwartz, R. C. Hornik, and K. Armstrong Risk Information Exposure and Direct-to-Consumer Genetic Testing for BRCA Mutations among Women with a Personal or Family History of Breast or Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., April 1, 2009; 18(4): 1303 - 1311. [Abstract] [Full Text] [PDF]

				L. Melchor, E. Honrado, J. Huang, S. Alvarez, T. L. Naylor, M. J. Garcia, A. Osorio, D. Blesa, M. R. Stratton, B. L. Weber, et al. Estrogen Receptor Status Could Modulate the Genomic Pattern in Familial and Sporadic Breast Cancer Clin. Cancer Res., December 15, 2007; 13(24): 7305 - 7313. [Abstract] [Full Text] [PDF]

				F. H. Vaz, P. M. Machado, R. D. Brandao, C. T. Laranjeira, J. S. Eugenio, A. H. Fernandes, and S. P. Andre Familial Breast/Ovarian Cancer and BRCA1/2 Genetic Screening: The Role of Immunohistochemistry as an Additional Method in the Selection of Patients J. Histochem. Cytochem., November 1, 2007; 55(11): 1105 - 1113. [Abstract] [Full Text] [PDF]

				J. N. Weitzel, V. I. Lagos, J. S. Herzog, T. Judkins, B. Hendrickson, J. S. Ho, C. N. Ricker, K. J. Lowstuter, K. R. Blazer, G. Tomlinson, et al. Evidence for Common Ancestral Origin of a Recurring BRCA1 Genomic Rearrangement Identified in High-Risk Hispanic Families Cancer Epidemiol. Biomarkers Prev., August 1, 2007; 16(8): 1615 - 1620. [Abstract] [Full Text] [PDF]

				J. N. Weitzel, V. I. Lagos, C. A. Cullinane, P. J. Gambol, J. O. Culver, K. R. Blazer, M. R. Palomares, K. J. Lowstuter, and D. J. MacDonald Limited Family Structure and BRCA Gene Mutation Status in Single Cases of Breast Cancer JAMA, June 20, 2007; 297(23): 2587 - 2595. [Abstract] [Full Text] [PDF]

				J. G. Guillem, W. C. Wood, J. F. Moley, A. Berchuck, B. Y. Karlan, D. G. Mutch, R. F. Gagel, J. Weitzel, M. Morrow, B. L. Weber, et al. ASCO/SSO Review of Current Role of Risk-Reducing Surgery in Common Hereditary Cancer Syndromes J. Clin. Oncol., October 1, 2006; 24(28): 4642 - 4660. [Abstract] [Full Text] [PDF]

				K. E. Malone, J. R. Daling, D. R. Doody, L. Hsu, L. Bernstein, R. J. Coates, P. A. Marchbanks, M. S. Simon, J. A. McDonald, S. A. Norman, et al. Prevalence and Predictors of BRCA1 and BRCA2 Mutations in a Population-Based Study of Breast Cancer in White and Black American Women Ages 35 to 64 Years Cancer Res., August 15, 2006; 66(16): 8297 - 8308. [Abstract] [Full Text] [PDF]

				M. J. Hall and O. I. Olopade Disparities in Genetic Testing: Thinking Outside the BRCA Box J. Clin. Oncol., May 10, 2006; 24(14): 2197 - 2203. [Abstract] [Full Text] [PDF]

				E. Honrado, A. Osorio, J. Palacios, R. L. Milne, L. Sanchez, O. Diez, A. Cazorla, K. Syrjakoski, D. Huntsman, P. Heikkila, et al. Immunohistochemical Expression of DNA Repair Proteins in Familial Breast Cancer Differentiate BRCA2-Associated Tumors J. Clin. Oncol., October 20, 2005; 23(30): 7503 - 7511. [Abstract] [Full Text] [PDF]

				R. Nanda, L. P. Schumm, S. Cummings, J. D. Fackenthal, L. Sveen, F. Ademuyiwa, M. Cobleigh, L. Esserman, N. M. Lindor, S. L. Neuhausen, et al. Genetic Testing in an Ethnically Diverse Cohort of High-Risk Women: A Comparative Analysis of BRCA1 and BRCA2 Mutations in American Families of European and African Ancestry JAMA, October 19, 2005; 294(15): 1925 - 1933. [Abstract] [Full Text] [PDF]

				J. N. Weitzel, V. Lagos, K. R. Blazer, R. Nelson, C. Ricker, J. Herzog, C. McGuire, and S. Neuhausen Prevalence of BRCA Mutations and Founder Effect in High-Risk Hispanic Families Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1666 - 1671. [Abstract] [Full Text] [PDF]

				J D Fackenthal, L Sveen, Q Gao, E K Kohlmeir, C Adebamowo, T O Ogundiran, A A Adenipekun, R Oyesegun, O Campbell, C Rotimi, et al. Complete allelic analysis of BRCA1 and BRCA2 variants in young Nigerian breast cancer patients J. Med. Genet., March 1, 2005; 42(3): 276 - 281. [Full Text] [PDF]

				C. Hughes, S. K. Peterson, A. Ramirez, K. J. Gallion, P. G. McDonald, C. S. Skinner, and D. Bowen Minority Recruitment in Hereditary Breast Cancer Research Cancer Epidemiol. Biomarkers Prev., July 1, 2004; 13(7): 1146 - 1155. [Abstract] [Full Text] [PDF]

				M. J. Dubin, P. H. Stokes, E. Y. M. Sum, R. S. Williams, V. A. Valova, P. J. Robinson, G. J. Lindeman, J. N. M. Glover, J. E. Visvader, and J. M. Matthews Dimerization of CtIP, a BRCA1- and CtBP-interacting Protein, Is Mediated by an N-terminal Coiled-coil Motif J. Biol. Chem., June 25, 2004; 279(26): 26932 - 26938. [Abstract] [Full Text] [PDF]

				F Marroni, P Aretini, E D'Andrea, M A Caligo, L Cortesi, A Viel, E Ricevuto, M Montagna, G Cipollini, S Ferrari, et al. Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations J. Med. Genet., April 1, 2004; 41(4): 278 - 285. [Full Text] [PDF]

				J. Palacios, E. Honrado, A. Osorio, A. Cazorla, D. Sarrio, A. Barroso, S. Rodriguez, J. C. Cigudosa, O. Diez, C. Alonso, et al. Immunohistochemical Characteristics Defined by Tissue Microarray of Hereditary Breast Cancer Not Attributable to BRCA1 or BRCA2 Mutations: Differences from Breast Carcinomas Arising in BRCA1 and BRCA2 Mutation Carriers Clin. Cancer Res., September 1, 2003; 9(10): 3606 - 3614. [Abstract] [Full Text] [PDF]